| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,097 | 0,138 | 11:02 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Intervacc AB: Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac | 88 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac, the company's innovative vaccine against strangles in... ► Artikel lesen | |
| Mi | Intervacc AB: Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit | 350 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit.... ► Artikel lesen | |
| 22.05. | Intervacc AB: Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials | 169 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards... ► Artikel lesen | |
| 15.05. | Emil Billbäck appointed new Chair of the Board of Intervacc | 2 | Cision News | ||
| INTERVACC Aktie jetzt für 0€ handeln | |||||
| 13.05. | Intervacc AB: Report from Annual General Meeting in Intervacc | 170 | GlobeNewswire (Europe) | Intervacc AB (publ) held its Annual General Meeting ("AGM") on Wednesday 13 May 2026, at which the following resolutions were made.
Adoption of the income statement and balance sheet
The AGM adopted... ► Artikel lesen | |
| 13.05. | Intervacc AB Q1 Sales Decline | 1 | RTTNews | ||
| 12.05. | Intervacc AB: Intervacc strengthens management team for future growth | 258 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac registered on 16 European markets, today announces that the company is strengthening its management team through... ► Artikel lesen | |
| 12.05. | Intervacc AB: Interim report January - March 2026 | 177 | GlobeNewswire (Europe) | The Group in summary
01/01/26
01/01/25
01/01/25
-31/03/26
-31/03/25
-31/12/25
Net... ► Artikel lesen | |
| 04.05. | INTERVACC AB: International Awareness Initiative Against Strangles | 2 | Cision News | ||
| 23.04. | Intervacc brings together leading US and European experts to jointly tackle strangles | 2 | Cision News | ||
| 16.04. | Intervacc AB: Unprecedented decision opens the way for the launch of Strangvac in Iceland | 205 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.
Strangles, a potentially lethal infection... ► Artikel lesen | |
| 14.04. | Intervacc publishes the 2025 Annual Report | 1 | Cision News | ||
| 10.04. | Notice of Annual General Meeting in Intervacc AB (publ) | 1 | Cision News | ||
| 19.03. | Intervacc AB: Intervacc announces breakthrough protection against Streptococcus suis infection in piglets | 233 | GlobeNewswire (Europe) | Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating... ► Artikel lesen | |
| 09.03. | Intervacc presents to the capital market on three occasions in March | 2 | Cision News | ||
| 17.02. | Intervacc AB Q4 Sales Decline | 1 | RTTNews | ||
| 17.02. | Intervacc AB: Year-end report January - December 2025 | 286 | GlobeNewswire (Europe) | The Group in summary
01/10/25
01/10/24
Full year
Full year
-31/12/25
-31/12/24
2025
2024
Net... ► Artikel lesen | |
| 05.02. | Intervacc AB: Intervacc announces change of CEO | 348 | GlobeNewswire (Europe) | The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.
Simultaneously, the Board has appointed... ► Artikel lesen | |
| 16.12.25 | Intervacc AB: Clinical studies with Strangvac have begun in the U.S. market | 228 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac in the U.S.
The initial... ► Artikel lesen | |
| 19.11.25 | Intervacc AB: Interim report January - September 2025 | 226 | GlobeNewswire (Europe) | The Group in summary
01/07/25
01/07/24
01/01/25
01/01/24
Full year
-30/09/25
-30/09/24
-30/09/25
-30/09/24
2024
Net... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,061 | -6,92 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NANOREPRO | 1,910 | -2,05 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
23.07.2026 / 09:01 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 8,010 | -0,87 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BRAIN BIOTECH | 2,810 | +1,44 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Personalentscheidungen / Vorstand
BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden... ► Artikel lesen | |
| AAP IMPLANTATE | 1,620 | +3,18 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| CO.DON | 0,013 | -16,67 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,830 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| CLINUVEL | 5,804 | -2,12 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| BIO-GATE | 0,700 | 0,00 % | Original-Research: Bio-Gate AG (von BankM AG): Kaufen | Original-Research: Bio-Gate AG - von BankM AG
27.07.2026 / 12:30 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,810 | +4,34 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,300 | +0,88 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| EXELIXIS | 49,300 | +1,98 % | Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? | ||
| EVONEXT | 2,200 | -2,65 % | EvoNext Holdings SA: EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026 | EvoNext Holdings SA
/ Key word(s): AGMEGM
EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026
20.05.2026 / 17:01 CET/CEST
PRESS... ► Artikel lesen |